Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Jan 08, 2019

Completion of Transfer of Marketing and Manufacturing Rights of 13 Long-Term Listed Products from Chugai to Taiyo Pharma

Company Name: Chugai Pharmaceutical Co., Ltd.
Representative: Tatsuro Kosaka, President and CEO
(Code: 4519, Listed on First Section of Tokyo Stock Exchange)
Contact: Masahiko Uchida, General Manager of Corporate Communications Dept.
Tel: 03-3273-0881
Representative: Eiji Sato, President and CEO
(Code: 4626, Listed on First Section of Tokyo Stock Exchange)
Contact: Shuichi Omi, Executive Officer, General Manager, Administrative Division
Tel: 03-5953-5200

Chugai Pharmaceutical Co., Ltd. (hereinafter “Chugai”) and TAIYO HOLDINGS CO., LTD. (hereinafter “Taiyo Holdings”) announced today that both parties completed the transfer of marketing authorization and marketing activities of 13 long-term listed products, manufactured and marketed in Japan, from Chugai to Taiyo Pharma Co., Ltd. (hereinafter “Taiyo Pharma”) on January 7, 2019. The details of the transfer had been announced on November 14, 2017 as “Marketing and Manufacturing Right Transfer of 13 Long-Term Listed Products from Chugai to Taiyo Pharma” as well as on January 5, 2018 as “Notice Concerning Execution of Asset Transfer of 13 Long-Term Listed Products from Chugai to Taiyo Pharma.”

Transfer of marketing and manufacturing rights of all formulation of the Products listed below were completed.

Brand Name Therapeutic Category
1 BACTRAMIN® Synthetic Antibacterial Agent / Agent for the treatment of Pneumocystis Pneumonia
2 DIGOSIN® Digitalis Glycoside
3 EUGLUCON® Oral Hypoglycemic Agent
4 FURTULON® Anti-Tumor Agent
5 GLYCEOL® Drug for the treatment of Intracranial Hypertension and Intracranial Edema / Ocular Hypotensive Agent
6 KYTRIL® 5-HT3 receptor antagonist for the treatment of Nausea and Vomiting
7 MADOPAR® Agent for the treatment of Parkinson’s disease
9 PYDOXAL® Active Form of Vitamin B6
10 RESPLEN® Antitussive and Mucolytic Agent
11 RIVOTRIL® Anti-epileptic Agent
12 ROCEPHIN® Cephalosporin Antibiotic
13 TIGASON® Agent for the treatment of Hyperkeratosis

The transfer of Products is not expected to have a material impact on the consolidated financials of Chugai for the fiscal year ending December 2019.

Impact of this matter on the consolidated financial results for the fiscal year ending March 2019 of Taiyo Holdings has been incorporated into the financial forecast announced on May 2, 2018.
If any revision of the financial forecast is required for disclosure in the future, it will be announced promptly.

Trademarks used or mentioned in this release are protected by law.

Announced on November 14, 2017:

Announced on January 5, 2018:


  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.
  • Tel: +81-3-3273-0881
  • Email:
  • Corporate Planning Dept., Administration Div.
  • Tel: +81-3-5953-5213
  • Email:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top